Effects of 2-methoxyestradiol on apoptosis and HIF-1α and HIF‑2α expression in lung cancer cells under normoxia and hypoxia

Aquino-Gálvez,Arnoldo; González-Ávila,Georgina; Delgado-Tello,Javier; Castillejos-López,Manuel; Mendoza-Milla,Criselda; Zúñiga,Joaquín; Checa,Marco; Maldonado-Martínez,Héctor Aquiles; Trinidad-López,Axel; Cisneros,José; Torres-Espíndola,Luz María; Hernández-Jiménez,Claudia; Sommer,Bettina; Cabello-Gutiérrez,Carlos; Gutiérrez-González,Luis H.

doi:10.3892/or.2015.4399

Effects of 2-methoxyestradiol on apoptosis and HIF-1α and HIF‑2α expression in lung cancer cells under normoxia and hypoxia

Authors:
- Arnoldo Aquino-Gálvez
- Georgina González-Ávila
- Javier Delgado-Tello
- Manuel Castillejos-López
- Criselda Mendoza-Milla
- Joaquín Zúñiga
- Marco Checa
- Héctor Aquiles Maldonado-Martínez
- Axel Trinidad-López
- José Cisneros
- Luz María Torres-Espíndola
- Claudia Hernández-Jiménez
- Bettina Sommer
- Carlos Cabello-Gutiérrez
- Luis H. Gutiérrez-González
View Affiliations

Affiliations: Instituto Nacional de Enfermedades Respiratorias ‘Ismael Cosío Villegas’, Mexico City, DF, Mexico, Instituto Nacional de Cancerología, Mexico City, DF, Mexico, Instituto Nacional de Pediatría, Mexico City, DF, Mexico
Published online on: November 4, 2015 https://doi.org/10.3892/or.2015.4399
Pages: 577-583
Copyright: © Aquino-Gálvez et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hypoxic tumor cells are known to be more resistant to conventional chemotherapy and radiation than normoxic cells. However, the effects of 2-methoxyestradiol (2-ME), an anti-angiogenic, antiproliferative and pro-apoptotic drug, on hypoxic lung cancer cells are unknown. The aim of the present study was to compare the effects of 2-ME on cell growth, apoptosis, hypoxia-inducible factor 1α (HIF-1α) and HIF-2α gene and protein expression in A549 cells under normoxic and hypoxic conditions. To establish the optimal 2-ME concentration with which to carry out the apoptosis assay and to examine mRNA and protein expression of HIFs, cell growth analysis was carried out through N-hexa-methylpararosaniline staining assays in A549 cell cultures treated with one of five different 2-ME concentrations at different times under normoxic or hypoxic growth conditions. The 2-ME concentration of 10 mM at 72 h was selected to perform all further experiments. Apoptotic cells were analyzed by flow cytometry. Western blotting was used to determine HIF-1α and HIF-2α protein expression in total cell extracts. Cellular localization of HIF-1α and HIF-2α was assessed by immunocytochemistry. HIF-1α and HIF-2α gene expression was determined by real‑time PCR. A significant increase in the percentage of apoptosis was observed when cells were treated with 2-ME under a normoxic but not under hypoxic conditions (p=0.006). HIF-1α and HIF-2α protein expression levels were significantly decreased in cells cultured under hypoxic conditions and treated with 2-ME (p<0.001). Furthermore, 2-ME decreased the HIF-1α and HIF-2α nuclear staining in cells cultured under hypoxia. The HIF-1α and HIF-2α mRNA levels were significantly lower when cells were exposed to 2-ME under normoxia and hypoxia. Our results suggest that 2-ME could have beneficial results when used with conventional chemotherapy in an attempt to lower the invasive and metastatic processes during cancer development due to its effects on the gene expression and protein synthesis of HIFs.

View Figures

View References

1	Lu X and Kang Y: Hypoxia and hypoxia-inducible factors: Master regulators of metastasis. Clin Cancer Res. 16:5928–5935. 2010.
2	Ye J, Wu D, Wu P, Chen Z and Huang J: The cancer stem cell niche: Cross talk between cancer stem cells and their microenvironment. Tumour Biol. 35:3945–3951. 2014.
3	Carmeliet P: VEGF as a key mediator of angiogenesis in cancer. Oncology. 69(Suppl 3): S4–S10. 2005.
4	Semenza GL: Hypoxia-inducible factor 1 and the molecular physiology of oxygen homeostasis. J Lab Clin Med. 131:207–214. 1998.
5	Semenza GL: HIF-1 and human disease: One highly involved factor. Genes Dev. 14:1983–1991. 2000.
6	Bertout JA, Patel SA and Simon MC: The impact of O₂ availability on human cancer. Nat Rev Cancer. 8:967–975. 2008.
7	Clerici C and Planès C: Gene regulation in the adaptive process to hypoxia in lung epithelial cells. Am J Physiol Lung Cell Mol Physiol. 296:L267–L274. 2009.
8	Fotsis T, Zhang Y, Pepper MS, Adlercreutz H, Montesano R, Nawroth PP and Schweigerer L: The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature. 368:237–239. 1994.
9	Becker CM, Rohwer N, Funakoshi T, Cramer T, Bernhardt W, Birsner A, Folkman J and D'Amato RJ: 2-methoxyestradiol inhibits hypoxia-inducible factor-1{alpha} and suppresses growth of lesions in a mouse model of endometriosis. Am J Pathol. 172:534–544. 2008.
10	Escuin D, Kline ER and Giannakakou P: Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function. Cancer Res. 65:9021–9028. 2005.
11	Chua YS, Chua YL and Hagen T: Structure activity analysis of 2-methoxyestradiol analogues reveals targeting of microtubules as the major mechanism of antiproliferative and proapoptotic activity. Mol Cancer Ther. 9:224–235. 2010.
12	D'Amato RJ, Lin CM, Flynn E, Folkman J and Hamel E: 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc Natl Acad Sci USA. 91:3964–3968. 1994.
13	Benedikt MB, Mahlum EW, Shogren KL, Subramaniam M, Spelsberg TC, Yaszemski MJ and Maran A: 2-methoxyestradiol-mediated anti-tumor effect increases osteoprotegerin expression in osteosarcoma cells. J Cell Biochem. 109:950–956. 2010.
14	Bu S, Blaukat A, Fu X, Heldin NE and Landström M: Mechanisms for 2-methoxyestradiol-induced apoptosis of prostate cancer cells. FEBS Lett. 531:141–151. 2002.
15	Rankin EB and Giaccia AJ: The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ. 15:678–685. 2008.
16	Kilic M, Kasperczyk H, Fulda S and Debatin KM: Role of hypoxia inducible factor-1 alpha in modulation of apoptosis resistance. Oncogene. 26:2027–2038. 2007.
17	Sermeus A, Cosse JP, Crespin M, Mainfroid V, de Longueville F, Ninane N, Raes M, Remacle J and Michiels C: Hypoxia induces protection against etoposide-induced apoptosis: Molecular profiling of changes in gene expression and transcription factor activity. Mol Cancer. 7:272008.
18	Yu EZ, Li YY, Liu XH, Kagan E and McCarron RM: Antiapoptotic action of hypoxia-inducible factor-1 alpha in human endothelial cells. Lab Invest. 84:553–561. 2004.
19	Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, Willard MT, Zhong H, Simons JW and Giannakakou P: 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell. 3:363–375. 2003.
20	Brown JM and Wilson WR: Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer. 4:437–447. 2004.
21	Flamant L, Notte A, Ninane N, Raes M and Michiels C: Anti-apoptotic role of HIF-1 and AP-1 in paclitaxel exposed breast cancer cells under hypoxia. Mol Cancer. 9:1912010.
22	Sun HC, Qiu ZJ, Liu J, Sun J, Jiang T, Huang KJ, Yao M and Huang C: Expression of hypoxia-inducible factor-1 alpha and associated proteins in pancreatic ductal adenocarcinoma and their impact on prognosis. Int J Oncol. 30:1359–1367. 2007.
23	Swinson DE, Jones JL, Cox G, Richardson D, Harris AL and O'Byrne KJ: Hypoxia-inducible factor-1 alpha in non small cell lung cancer: Relation to growth factor, protease and apoptosis pathways. Int J Cancer. 111:43–50. 2004.
24	Kuo KL, Lin WC, Ho IL, Chang HC, Lee PY, Chung YT, Hsieh JT, Pu YS, Shi CS and Huang KH: 2-methoxyestradiol induces mitotic arrest, apoptosis, and synergistic cytotoxicity with arsenic trioxide in human urothelial carcinoma cells. PLoS One. 8:e687032013.
25	Zhou NN, Zhu XF, Zhou JM, Li MZ, Zhang XS, Huang P and Jiang WQ: 2-Methoxyestradiol induces cell cycle arrest and apoptosis of nasopharyngeal carcinoma cells. Acta Pharmacol Sin. 25:1515–1520. 2004.
26	Rajkumar SV, Richardson PG, Lacy MQ, Dispenzieri A, Greipp PR, Witzig TE, Schlossman R, Sidor CF, Anderson KC and Gertz MA: Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma. Clin Cancer Res. 13:6162–6167. 2007.
27	Sweeney C, Liu G, Yiannoutsos C, Kolesar J, Horvath D, Staab MJ, Fife K, Armstrong V, Treston A, Sidor C, et al: A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer. Clin Cancer Res. 11:6625–6633. 2005.
28	James J, Murry DJ, Treston AM, Storniolo AM, Sledge GW, Sidor C and Miller KD: Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer. Invest New Drugs. 25:41–48. 2007.
29	Matei D, Schilder J, Sutton G, Perkins S, Breen T, Quon C and Sidor C: Activity of 2 methoxyestradiol (Panzem NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: A Hoosier Oncology Group trial. Gynecol Oncol. 115:90–96. 2009.
30	Bottsford-Miller JN, Coleman RL and Sood AK: Resistance and escape from antiangiogenesis therapy: Clinical implications and future strategies. J Clin Oncol. 30:4026–4034. 2012.
31	Ma L, Li G, Zhu H, Dong X, Zhao D, Jiang X, Li J, Qiao H, Ni S and Sun X: 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2. Cancer Lett. 355:96–105. 2014.
32	Semenza GL: Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today. 12:853–859. 2007.
33	Harris AL: Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer. 2:38–47. 2002.
34	Teicher BA, Holden SA, al-Achi A and Herman TS: Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma. Cancer Res. 50:3339–3344. 1990.
35	Mueck AO and Seeger H: 2-Methoxyestradiol - biology and mechanism of action. Steroids. 75:625–631. 2010.
36	Piret JP, Mottet D, Raes M and Michiels C: Is HIF-1alpha a pro-or an anti-apoptotic protein? Biochem Pharmacol. 64:889–892. 2002.
37	Greijer AE and van der Wall E: The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J Clin Pathol. 57:1009–1014. 2004.
38	Shen H, Yang Y, Xia S, Rao B, Zhang J and Wang J: Blockage of Nrf2 suppresses the migration and invasion of esophageal squamous cell carcinoma cells in hypoxic microenvironment. Dis Esophagus. 27:685–692. 2014.
39	Visagie MH and Joubert AM: In vitro effects of 2-methoxyestra-diol-bis-sulphamate on reactive oxygen species and possible apoptosis induction in a breast adenocarcinoma cell line. Cancer Cell Int. 11:432011.
40	Stander BA, Marais S, Vorster CJ and Joubert AM: In vitro effects of 2-methoxyestradiol on morphology, cell cycle progression, cell death and gene expression changes in the tumorigenic MCF-7 breast epithelial cell line. J Steroid Biochem Mol Biol. 119:149–160. 2010.
41	Vorster C and Joubert A: In vitro effects of 2-methoxyestradiol-bis-sulphamate on cell growth, morphology and cell cycle dynamics in the MCF-7 breast adenocarcinoma cell line. Biocell. 34:71–79. 2010.
42	Chander SK, Foster PA, Leese MP, Newman SP, Potter BV, Purohit A and Reed MJ: In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyoestradiol. Br J Cancer. 96:1368–1376. 2007.
43	Tevaarwerk AJ, Holen KD, Alberti DB, Sidor C, Arnott J, Quon C, Wilding G and Liu G: Phase I trial of 2-methoxyestra-diol NanoCrystal dispersion in advanced solid malignancies. Clin Cancer Res. 15:1460–1465. 2009.
44	Visagie M, Theron A, Mqoco T, Vieira W, Prudent R, Martinez A, Lafanechère L and Joubert A: Sulphamoylated 2-methoxyestra-diol analogues induce apoptosis in adenocarcinoma cell lines. PLoS One. 8:e719352013.
45	Ricker JL, Chen Z, Yang XP, Pribluda VS, Swartz GM and Van Waes C: 2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma. Clin Cancer Res. 10:8665–8673. 2004.
46	Sato M, Tanaka T, Maeno T, Sando Y, Suga T, Maeno Y, Sato H, Nagai R and Kurabayashi M: Inducible expression of endothelial PAS domain protein-1 by hypoxia in human lung adenocarcinoma A549 cells. Role of Src family kinases-dependent pathway. Am J Respir Cell Mol Biol. 26:127–134. 2002.
47	Uchida T, Rossignol F, Matthay MA, Mounier R, Couette S, Clottes E and Clerici C: Prolonged hypoxia differentially regulates hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression in lung epithelial cells: Implication of natural antisense HIF-1alpha. J Biol Chem. 279:14871–14878. 2004.
48	Wu XH, Qian C and Yuan K: Correlations of hypoxia-inducible factor-1α/hypoxia-inducible factor-2α expression with angio-genesis factors expression and prognosis in non-small cell lung cancer. Chin Med J. 124:11–18. 2011.
49	Kim WY, Perera S, Zhou B, Carretero J, Yeh JJ, Heathcote SA, Jackson AL, Nikolinakos P, Ospina B, Naumov G, et al: HIF2α cooperates with RAS to promote lung tumorigenesis in mice. J Clin Invest. 119:2160–2170. 2009.